Xiaojun Zhang is a Neurology physician affiliated with The Ohio State University Wexner Medical Center. OpenAlex indexes 76 publications with 926 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2050 Kenny Rd
Columbus, OH 432213502
Telephone
614-293-4969Provider last certified this registry record 13 Oct 2025.
Clinical trials
- A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）
Sponsor: Drug Induced Liver Disease Study Group
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Biogen, Inc.Program year20231 payment
- Horizon Therapeutics plcProgram year20231 payment
- Horizon Therapeutics plcProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
39.8%Gabapentinoids29.1%Gabapentin100%Part D<11 patientsMood Stabilizer10.7%Carbamazepine Er100%Part D<11 patientsMusculoskeletal
35.9%gamma-Aminobutyric Acid-ergic Agonist19.4%Baclofen100%Part D<11 patientsCentral alpha-2 Adrenergic Agonist16.5%Tizanidine Hcl100%Part D<11 patientsMetabolism & gastrointestinal
13.6%Corticosteroid13.6%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer
International Immunopharmacology
2025 - FedSSU: flexible and efficient decentralized unlearning for federated learning
The Journal of Supercomputing
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Pawlik, MD
The Ohio State University Wexner Medical Center
Colleen Cebulla, MD
The Ohio State University Wexner Medical Center
Michael Grever, MD
The Ohio State University Wexner Medical Center
Brad Rovin, MD
The Ohio State University Wexner Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”